Skip to content

WARQUIGNIESPHARMA

Active
Private limited companyfounded 2011active for 15 yearsPavé de Warquignies 108, 7340 Colfontaine, BelgiumKBO/BCE: BE 0835.684.001
Summary

WARQUIGNIESPHARMA has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €212,960 and a net result of €45,184. Equity is growing by about 62% per year across the filed financial years. Its solvency ranks better than 81% of 22,595 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow ReportCompare
WARQUIGNIESPHARMAActiveChecked score 98/100
Risk analysis ReportCompare

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
≈ €440,000turnover 2025, estimated
Staff
1 FTE
Equity
€212,960
Profit
€45,184
Turnover estimated from the gross margin
Financial health
98 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
2025 accounts on time2 of 3 deeds summarised
Why 98raises risk1 of the last 3 latelowers riskLiquidity: current ratio 3.18, cash €138,121Equity €212,960 (71.1% of total assets)Founded in 2011Show the evidence

Checked score

Score 2025
98 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 83% of its sector peers (NACE 47, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 96+19
equity 71.1% of total assets
Liquidity 88+5
short-term debt 28.9% · cash 46.1%
Profitability 88-4
return on assets 15.1%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,259 companies, NACE 47, micro)
Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.2%● unchanged vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.2%● unchanged vs 06-2025 08-2025: 0.4%▲ +0.2 percentage points vs 07-2025 09-2025: 0.5%▲ +0.1 percentage points vs 08-2025 10-2025: 0.8%▲ +0.3 percentage points vs 09-2025highest value 11-2025: 0.4%▼ -0.4 percentage points vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.3%▼ -0.1 percentage points vs 12-2025 02-2026: 0.3%● unchanged vs 01-2026 03-2026: 0.3%● unchanged vs 02-2026 04-2026: 0.3%● unchanged vs 03-2026 05-2026: 0.3%● unchanged vs 04-2026 06-2026: 0.3%● unchanged vs 05-2026 07-2026: 0.3%● unchanged vs 06-2026 08-2026: 0.1%▼ -0.2 percentage points vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026lowest value
Credit of up to €20,000 on 30-day terms is acceptable
Liquidity ample (current ratio 3.18, compared with 2.29 in 2024, above the usual 1.5; short-term debt: 28.9% and cash: 46.1% of total assets), and 28.9% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 82% on solvency, 90% on liquidity, 82% on profitability and 78% on growth.

The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 3.18, cash €138,121
NBB · annual accounts
lowers risk · Equity €212,960 (71.1% of total assets)
NBB · annual accounts
raises risk · 1 of the last 3 late
NBB · filings
lowers risk · Founded in 2011
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-07-2026, 0 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
on the day
2024
77 days late
2023
58 days early
2022
53 days late
2021
29 days late
2020
12 days early
2019
25 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 16 days after the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (4 of the last 5 filed years within 48 days of that day).
Companies Code · seven months
Where today falls in the filing period
28-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. Resignation: TASSIN Paul (director)Appointment: HOUDART Marjorie (director) ·…
  3. Equity above €200,000equity €212,960 ▲26.9%

Key points

  • Positive: Among the best 14% on net resultsector median €5,085 · 22,576 companies €45,184 View
  • Positive: 7 profitable years in a rowprofit 2025: €45,184 7 years View
  • Board changedlatest change 25-02-2026 · 2 in office 1 joined · 1 left View

By topic

Financials

Financial year
2025
Total assets
€299,659
Profit
€45,184
Solvency
71.1%
Total assets▼ 7.4%
Net result
20182025
Go to Financials

Timeline

Events
21
Since
2013
Next accounts
by 31-07-2027
  1. 16-10-2025Annual accounts filed
  2. 31-12-2024Highest result from 2018 to 2025
  3. 31-12-2024Equity above €150,000
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
20-04-2011
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Key facts about WARQUIGNIESPHARMA

What is the company number of WARQUIGNIESPHARMA?
0835.684.001. In Belgium the VAT number is the company number with BE in front: BE 0835.684.001.
Where is WARQUIGNIESPHARMA based?
The registered office is at Pavé de Warquignies 108, 7340 Colfontaine.Company details
What does WARQUIGNIESPHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of WARQUIGNIESPHARMA?
Private limited company (BV).
When was WARQUIGNIESPHARMA founded?
On 20-04-2011.
Is WARQUIGNIESPHARMA still active?
Yes, WARQUIGNIESPHARMA is an active enterprise in the KBO register.
How many employees does WARQUIGNIESPHARMA have?
On average 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of WARQUIGNIESPHARMA?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is WARQUIGNIESPHARMA profitable?
In financial year 2025, WARQUIGNIESPHARMA made a profit of €45,184.
Where can I find the annual accounts of WARQUIGNIESPHARMA?
WARQUIGNIESPHARMA filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of WARQUIGNIESPHARMA due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to WARQUIGNIESPHARMA

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure